Hsi-Feng Tu - Search Results

Year	Number of Results
2002	1
2005	1
2007	1
2008	2
2009	2
2010	3
2011	2
2012	4
2013	3
2014	2
2015	3
2016	3
2017	3
2018	2
2019	3
2020	4
2021	8
2022	8
2023	4
2024	2

1

MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance.

Tu HF, Lin SC, Chang KW. Tu HF, et al. Curr Opin Otolaryngol Head Neck Surg. 2013 Apr;21(2):104-11. doi: 10.1097/MOO.0b013e32835e1d6e. Curr Opin Otolaryngol Head Neck Surg. 2013. PMID: 23340306 Review.

2

Locational effects on oral microbiota among long-term care patients.

Tsai FT, Wang DH, Yang CC, Lin YC, Huang LJ, Tsai WY, Li CW, Hsu WE, Tu HF, Hsu ML. Tsai FT, et al. Among authors: tu hf. J Oral Microbiol. 2022 Feb 14;14(1):2033003. doi: 10.1080/20002297.2022.2033003. eCollection 2022. J Oral Microbiol. 2022. PMID: 35186212 Free PMC article.

3

Profiles of oral microbiome associated with nasogastric tube feeding.

Wang DH, Tsai FT, Tu HF, Yang CC, Hsu ML, Huang LJ, Lin CT, Hsu WE, Lin YC. Wang DH, et al. Among authors: tu hf. J Oral Microbiol. 2023 Apr 11;15(1):2200898. doi: 10.1080/20002297.2023.2200898. eCollection 2023. J Oral Microbiol. 2023. PMID: 37063979 Free PMC article.

4

Arecoline-regulated ataxia telangiectasia mutated expression level in oral cancer progression.

Tu HF, Chen MY, Lai JC, Chen YL, Wong YW, Yang CC, Chen HY, Hsia SM, Shih YH, Shieh TM. Tu HF, et al. Head Neck. 2019 Aug;41(8):2525-2537. doi: 10.1002/hed.25718. Epub 2019 Feb 28. Head Neck. 2019. PMID: 30821076

5

Exploiting salivary miR-375 as a clinical biomarker of oral potentially malignant disorder.

Tu HF, Lin LH, Chang KW, Cheng HW, Liu CJ. Tu HF, et al. J Dent Sci. 2022 Apr;17(2):659-665. doi: 10.1016/j.jds.2021.09.020. Epub 2021 Sep 20. J Dent Sci. 2022. PMID: 35756782 Free PMC article.

6

Establishment of syngeneic murine model for oral cancer therapy.

Chen YF, Chang KW, Yang IT, Tu HF, Lin SC. Chen YF, et al. Among authors: tu hf. Oral Oncol. 2019 Aug;95:194-201. doi: 10.1016/j.oraloncology.2019.06.026. Epub 2019 Jun 28. Oral Oncol. 2019. PMID: 31345390

7

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.

Chiang IT, Lee YH, Tan ZL, Hsu FT, Tu HF. Chiang IT, et al. Among authors: tu hf. Biomed Pharmacother. 2022 Mar;147:112661. doi: 10.1016/j.biopha.2022.112661. Epub 2022 Jan 26. Biomed Pharmacother. 2022. PMID: 35092865 Free article.

8

The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.

Chang SR, Chou CH, Liu CJ, Lin YC, Tu HF, Chang KW, Lin SC. Chang SR, et al. Among authors: tu hf. Int J Mol Sci. 2023 Mar 21;24(6):5931. doi: 10.3390/ijms24065931. Int J Mol Sci. 2023. PMID: 36983005 Free PMC article.

9

Aberrant miR-10b, miR-372, and miR-375 expression in the cytobrushed samples from oral potentially malignant disorders.

Tu HF, Chang KW, Lin SC, Hung WW, Ji SH, Wu HL, Liu CJ. Tu HF, et al. J Dent Sci. 2022 Apr;17(2):688-695. doi: 10.1016/j.jds.2021.07.010. Epub 2021 Jul 30. J Dent Sci. 2022. PMID: 35756791 Free PMC article.

10

Co-upregulation of miR-31 and its host gene lncRNA MIR31HG in oral squamous cell carcinoma.

Tu HF, Liu CJ, Hung WW, Shieh TM. Tu HF, et al. J Dent Sci. 2022 Apr;17(2):696-706. doi: 10.1016/j.jds.2021.11.006. Epub 2021 Nov 27. J Dent Sci. 2022. PMID: 35756773 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

52 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year